APP
PRQR icon

Alpha Paradigm Partners’s ProQR Therapeutics PRQR Stock Holding History

Alpha Paradigm Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44,323
Closed -$371K – 643
2021
Q3 		$371K Buy
+44,323
New +$290K 0.15% 225

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Alpha Paradigm Partners's PRQR Position: Q4 2021 in Review

Alpha Paradigm Partners sold out of ProQR Therapeutics (PRQR) in Q4 2021, closing a stake of 44,323 shares — an estimated $371K sold.

Alpha Paradigm Partners first reported a position in PRQR in Q3 2021 and held it in 1 quarter. The position peaked at $371K in Q3 2021. 74 funds tracked by Wall St. Rank hold PRQR as of Q4 2021.

  • Alpha Paradigm Partners reported no remaining ProQR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Alpha Paradigm Partners sold 44,323 ProQR Therapeutics shares in Q4 2021, an estimated $371K.
  • Alpha Paradigm Partners first reported a position in ProQR Therapeutics in Q3 2021 and held it in 1 quarter.
  • Alpha Paradigm Partners's ProQR Therapeutics position peaked at $371K in Q3 2021.
  • 74 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2021.

Based on Alpha Paradigm Partners's 13F filing for Q4 2021, filed 14 Feb 2022.